Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Evidence-based care and outcomes improve at Get With The Guidelines -- Stroke hospitals

24.02.2010
Study highlights:
- A study looking at the first 1 million patients in the Get With The Guideline–Stroke program shows significant improvement in the use of evidence-based stroke therapies at participating hospitals.
- Among hospitals participating in the program, there were significant reductions in in-hospital death after ischemic stroke and transient ischemic attacks from 2003 to 2009.
- Researchers say this study demonstrates the value of quality improvement programs, such as Get With The Guidelines–Stroke, for improving the care and outcomes for stroke patients and providing a rich database of information for stroke research.

American Heart Association rapid access journal report:

Acute stroke care and clinical outcomes have improved significantly at hospitals participating in the American Heart Association/American Stroke Association’s Get With The Guidelines–Stroke program, according to a large study in Circulation: Cardiovascular Quality and Outcomes, a journal of the American Heart Association.

To better characterize contemporary stroke patients and determine the impact of Get With The Guidelines–Stroke participation, researchers analyzed several aspects of the first 1 million stroke patients at 1,392 hospitals participating in the quality improvement initiative from 2003 to 2009.

Each year more than 795,000 Americans suffer a stroke and another 200,000 to 500,000 present with a transient ischemic attack (TIA), often called a “warning stroke.”

“We found that the opportunities to provide guideline-recommended care addressed by the performance measures were substantially met for stroke and TIA patients, with overall composite care improving substantially from 72 percent in 2003 to 93 percent in 2009,” said Gregg C. Fonarow, M.D., lead author of the study and professor of cardiovascular medicine at the University of California-Los Angeles. “Stroke and TIA patients receiving all of the care measures for which they were eligible increased from 44 percent in 2003 to 84 percent in 2009.”

Patients in the database were an average 70.1 years of age. Of all strokes analyzed, ischemic strokes (caused by a blood clot blocking a blood vessel in the brain) were the most common (60.2 percent), followed by TIAs (22.8 percent), intracerebral hemorrhages (10.9 percent), subarachnoid hemorrhages (3.5 percent) and unclassified strokes (2.7 percent).

In-hospital mortality was highest among patients suffering hemorrhagic strokes (caused by blood leaking into the brain tissue). Hospital participation in Get With The Guidelines–Stroke made the biggest impact on stroke death rates among the most common stroke types – ischemic stroke and TIA – reducing the risk-adjusted odds of in-hospital mortality rate after ischemic stroke by 10 percent.

“The study has shown what is of primary importance to those who rely on the nation’s hospitals for optimal stroke care: the implementation of Get With The Guidelines–Stroke has resulted in substantial improvement in care at a rapid pace in a variety of hospital types and in multiple hospitals, simultaneously,” said Lee H. Schwamm, M.D., study co-author, chair of the Get With The Guidelines National Steering Committee and director of the TeleStroke and Acute Stroke Services at Massachusetts General Hospital in Boston, Mass.

The initiative is making a landmark contribution to stroke patients of today and tomorrow, said Clyde W. Yancy, M.D., president of the American Heart Association.

“Not only has quality improved, but lives are being saved and subsequent strokes are being thwarted,” said Yancy, medical director at the Baylor Heart and Vascular Institute in Dallas. “These findings demonstrate the true potential of implementing best practices within a care delivery system and the approach taken by the Get With The Guidelines team is a template for the future.” To facilitate better treatment and outcomes for stroke patients, the American Heart Association/American Stroke Association has launched Target: Stroke. The program will arm healthcare providers with information and tools to improve the use of the intravenous thrombolysis recombinent tissue plasminogen activator (IV rt-PA), the only drug approved by the U.S. Food and Drug Administration for the urgent treatment of ischemic stroke.

“An earlier analysis of Get With The Guidelines–Stroke data found that despite clinical trial evidence of improved outcomes for stroke patients treated early with an intravenous clot buster, only 27.4 percent of patients treated with IV rt-PA had door-to-needle times within 60 minutes,” Yancy said. “The goal for Target: Stroke is to achieve a door-to-needle time within 60 minutes or less in at least 50 percent of ischemic stroke patients treated with a clot-busting drug.

“The new initiative builds on this robust database we have from Get With The Guidelines to help us identify best practices that enable hospitals to further improve quality of care and outcomes in acute stroke care.”

Additional co-authors are Mathew J. Reeves, Ph.D.; Eric E. Smith, M.D., M.P.H.; Jeffrey L. Saver, M.D.; Xin Zhao, M.S.; DaiWai Olson, Ph.D.; Adrian F Hernandez, M.D. M.H.S.; and Eric D. Peterson, M.D., M.P.H. Author disclosures are on the manuscript.

Get With The Guidelines–Stroke is supported in part by an unrestricted educational grant from Merck/Schering-Plough Pharmaceutical.

Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.

NR10– 1041 (CircQO/Fonarow)

Cathy Lewis | EurekAlert!
Further information:
http://www.heart.org

More articles from Studies and Analyses:

nachricht New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg

nachricht Disarray in the brain
18.12.2017 | Universität zu Lübeck

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>